Erectile dysfunction (ED) is a common problem with a multifactorial aetiology. The treatment of ED has been revolutionised by the introduction of intracavernosal injections some two decades ago. However, the recent development of the orally-administered drug sildenafil (Viagra) has had a major impact on the treatment of ED. We discuss the trials with sildenafil with special reference to cardiovascular risk factors associated with ED.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2000) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: